In addition to the analysis of BRCA1/2 in tumour samples, some assays also include measurement of HRD by NGS analysis of genome-wide SNPs, including assessment of loss of heterozygosity (LOH) and/or other markers of genomic instability. The gene discussed is BRCA1; the disease is neoplasm.